Evidence map›Paper›PMID 39625520›Full record

ReviewCellular and molecular life sciences : CMLS2024

The concealed side of caspases: beyond a killer of cells.

Lina Abdelghany, Chanin Sillapachaiyaporn, Boris Zhivotovsky

Abstract readReview
In one paragraph

Review in Cellular and molecular life sciences : CMLS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Lina AbdelghanyInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
Chanin SillapachaiyapornInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SE-171 77, Sweden.
Boris ZhivotovskyInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, SE-171 77, Sweden. boris.zhivotovsky@ki.se.ORCID http://orcid.org/0000-0002-2238-3482

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the late 20th century, researchers have known that caspases are a pillar of cell death, particularly apoptosis. However, recent advances in cell biology have unraveled the multiple roles of caspases. These enzymes have an unconventional role in cell proliferation, differentiation, and invasion. As a result, caspase deregulation can fuel the fire of cancer, incite flames of inflammation, flare neurodegenerative disorders, and exacerbate skin pathologies. Several therapeutic approaches toward caspase inhibition have been investigated, but can caspase inhibitors harness the maladaptive effect of these proteases without causing significant side effects? A few studies have exploited caspase induction for cancer or adoptive cell therapies. Here, we provide a compelling picture of caspases, starting with their evolution, their polytomous roles beyond cell death, the flaws of their deregulation, and the merits of targeting them for therapeutic implications. Furthermore, we provide a deeper understanding of the evolution of caspase-related research up to the current era, pinpointing the role of caspases in cell survival and aiding in the development of effective caspase-targeted therapies.

Indexed as

ApoptosisCaspasesNeoplasmsAnimalsCaspase InhibitorsCell SurvivalHumansNeurodegenerative DiseasesCaspase InhibitorsCaspasesCancerCaspaseCell deathDifferentiationInflammationNeurodegenerative diseaseProliferationSurvival

Identifiers

PMID39625520
PMCPMC11615176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.